AccuSite injectable gel formulation of 5-FU data

Interim results in 15 squamous cell carcinoma patients in a Phase II trial showed that 100 percent of treated lesions achieved a complete response, as confirmed histologically after surgical removal.

AccuSite was injected directly into lesions once weekly for six weeks at a dose of 1ml, after which patients were followed for 16 weeks. ...